Anti-oxidative Amino Acid L-ergothioneine Modulates the Tumor Microenvironment to Facilitate Adjuvant Vaccine Immunotherapy
Open Access
- 4 April 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 10, 671
Abstract
Cancer vaccines consist of a tumor-associated antigen (TAA) and adjuvant. These vaccines induce and activate proliferation of TAA-specific cytotoxic T lymphocytes (CTLs), suppressing tumor growth. The therapeutic efficacy of TAA-specific CTLs depends on the properties of tumor microenvironment. The environments make immunosuppressive by function of regulatory T cells and tumor-associated myeloid cells; thus, regulation of these cells is important for successful cancer immunotherapy. We report here that L-ergothioneine (EGT) with the adjuvant Toll-like receptor 2 (TLR2) ligand modulated suppressive microenvironments to be immune-enhancing. EGT did not augment DC-mediated CTL priming or affect CTL activation in draining lymph node and spleen. However, EGT decreased the immuno-suppressive function of tumor-associated macrophages (TAMs). TLR2 stimulation accompanied with EGT administration downregulated expression of PD-L1, CSF-1R, arginase-1, FAS ligand, and TRAIL in TAMs, reflecting reduction of CTL suppression. An anti-oxidative thiol-thione residue of EGT was essential to dampening CTL suppression. The effect was specific to the thiol-thione residue of EGT because no effect was observed with another anti-oxidant N-acetyl-L-cysteine (NAC). A CTL-suppressive environment made by TLR2 is relieved to be improved by the addition of EGT, which may ameliorate the efficacy of vaccine immunotherapy.Keywords
This publication has 44 references indexed in Scilit:
- Cross-presentation by dendritic cellsNature Reviews Immunology, 2012
- Ergothioneine; antioxidant potential, physiological function and role in diseaseBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2012
- The Tissue Microlocalisation and Cellular Expression of CD163, VEGF, HLA-DR, iNOS, and MRP 8/14 Is Correlated to Clinical Outcome in NSCLCPLOS ONE, 2011
- Evaluation of the safety of the dietary antioxidant ergothioneine using the bacterial reverse mutation assayToxicology, 2010
- Functional Expression of Carnitine/Organic Cation Transporter OCTN1/SLC22A4 in Mouse Small Intestine and LiverDrug Metabolism and Disposition, 2010
- Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigensJournal of Experimental Medicine, 2010
- Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasisNature, 2009
- Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancerNature Medicine, 2007
- Tetramer‐blocking assay for defining antigen‐specific cytotoxic T lymphocytes using peptide‐MHC tetramerCancer Science, 2006
- Introduction of soluble protein into the class I pathway of antigen processing and presentationCell, 1988